RRRaffaele Romano

Raffaele Romano

*This is an algorithmically generated author record based on publicly available information.

Raffaele Romano has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Graziano Pinna

    The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, IL, USA; UI Center on Depression and Resilience (UICDR), Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, IL, USA; Center for Alcohol Research in Epigenetics (CARE), Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, IL, USA

    2 shared publications
  • Jordan C. Barone

    University of Illinois at Chicago Chicago Illinois USA

    2 shared publications
  • Anisha Nagpal

    Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA

    1 shared publication
  • Anna Patterson

    Department of Psychiatry, University of Illinois Chicago, Chicago, Illinois

    1 shared publication
  • Antonio Salerno

    The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, USA

    1 shared publication
  • Antonio Salerno

    The Psychiatric Institue, Department of Psychiatry, College of Medicine,University of Illinois Chicago,Chicago,United States, USA

    1 shared publication

Latest Publications

  • Open Access

    A Blood-Based Platform for Integrated GABAergic, Neurosteroidogenic, and Epigenetic Profiling in Women’s Mental Health and Beyond

    by Majd Aljurdi, Antonio Salerno, Jordan Barone, Raffaele Romano, John M Davis, Elizabeth Wenzel, Liisa Hantsoo, Jennifer L. Payne, Tory Eisenlohr-Moul, Graziano Pinna

    Women’s mental health remains underrepresented in biomedical research despite the substantial burden associated with postpartum depression, premenstrual dysphoric disorder, anxiety disorders, major depressive disorder, and related psychiatric conditions that are more common in women than men. Progress in biological characterization and biomarker development has been constrained by the limited availability of validated, standardized methods that account for reproductive stage, hormonal fluctuations, and sex-specific biology. Neuroactive steroids, including allopregnanolone, regulate neuronal excitability and stress responsivity through modulation of γ-aminobutyric acid type A (GABA-A) receptors. Alterations in neurosteroid biosynthesis, GABA-A receptor plasticity, and their coordinated regulation may therefore contribute to vulnerability across reproductive transitions and other periods of increased risk for mood disorders. Moreover, genes encoding neurosteroidogenic enzymes and GABA-A receptor subunits are susceptible to epigenetic regulation in response to hormonal, inflammatory, traumatic, and environmental exposures. This study aims to establish and validate a blood-based molecular platform for detecting and quantifying the expression of GABA-A receptor subunits; neurosteroidogenic enzymes, including 5α-reductase types 1 and 2, 5β-reductase, and 3α- and 3β-hydroxysteroid dehydrogenases; and epigenetic regulators from the ten-eleven translocation, histone deacetylase, and DNA methyltransferase. Whole blood provides a minimally invasive matrix suitable for repeated longitudinal assessment. Integrating these neurobiological signatures may provide a more comprehensive representation of the neurosteroid–GABAergic axis and its epigenetic regulation than examining individual markers alone. This methodological platform is intended to support future studies of biological vulnerability, disease progression, and treatment response, thereby facilitating the translation of experimental neurosteroid research into clinically relevant applications in women’s mental health and psychiatric populations more broadly.

  • Open Access

    Peripheral cyclical expression of GABA-A receptor subunit genes and menstrual cycle affective change: a dimensional, transdiagnostic study

    by Jordan C. Barone, Raffaele Romano, Anisha Nagpal, Antonio Salerno, Anna Patterson, Elizabeth S. Wenzel, Gabriela Guzman, Viraja Alluri, Pauline Maki, Graziano Pinna, et al.

    Menstrual cycle affective change (MCAC), including conditions like Premenstrual Dysphoric Disorder (PMDD), is triggered by ovarian hormone fluctuations, but its neurobiological mechanisms remain poorly understood. A leading hypothesis implicates abnormal GABA-A receptor (GABAAR) subunit regulation in altering sensitivity to neuroactive steroids, a theory difficult to test in humans. We examined peripheral mRNA expression of GABRD, GABRG2, and GABRA5 in a transdiagnostic sample of 112 participants (75 psychiatric outpatients with suicidality; 37 controls) to capture a dimensional range of MCAC severity. Participants provided daily affect ratings and five LH-timed blood samples using PAXgene tubes for RT-PCR analysis. Replicating preclinical findings, GABRG2 expression decreased during the midluteal phase. Critically, individual differences in both person-mean expression and perimenstrual change (AUCi) were correlated with cyclical symptom trajectories. Greater perimenstrual increases or higher average expression were associated with classic luteal-phase worsening of anxiety (GABRG2, GABRA5), irritability (GABRG2), and suicidal ideation (GABRG2, GABRA5, GABRD). However, relative to those with moderate or stable expression, perimenstrual decreases or lower average expression were also linked to cyclical worsening of anxiety and suicidal ideation that emerged around menses and persisted into the follicular phase. Overall, more stable subunit expression was associated with less cyclical symptom change. These findings could be consistent with a loss of homeostatic stability in GABAergic plasticity, rather than a simple unidirectional differences in levels or changes, as a potential correlate of MCAC. Peripheral GABAAR gene expression warrants further investigation, particularly in experimental studies, to determine whether there are causal associations between subunit gene expression and MCAC.